Drawing for METADICHOL

USPTO serial 77808847

METADICHOL

Reviewed by CopyMark Law Group

Reg. 3978756Status 710
Filing date
Status date
Registration date
Jun 14, 2011
Examiner
GARDNER, DAWNA BERYL
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with METADICHOL?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
005Analgesic and muscle relaxant pharmaceutical preparations; Anti-diabetic pharmaceuticals; Cardiovascular pharmaceuticals; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; for the treatment of inflammatory disorders; for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the prevention of DIABETES; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of HYPERTENSION; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in urology; Pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Pharmaceutical products for ophthalmological use; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical solutions used in dialysis; Pharmaceuticals, namely, lipid lowering agents; Plant extracts for medical, veterinary and pharmaceutical purposes; Therapeutic pharmaceutical for the treatment of OBESITYSECTION 8 - CANCELLEDOct 10, 2010

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jan 19, 2018C8..CANCELLED SEC. 8 (6-YR)—
Jun 14, 2016REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Jun 14, 2011R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
May 13, 2011SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
May 12, 2011REGVLAW OFFICE REGISTRATION REVIEW COMPLETED—
May 12, 2011CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
May 12, 2011XAECEXAMINER'S AMENDMENT ENTERED—
May 12, 2011GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
May 12, 2011GNEAEXAMINERS AMENDMENT E-MAILED—
May 12, 2011SNEASU-EXAMINER'S AMENDMENT WRITTEN—
May 11, 2011RDX3NOTIFICATION FOR REQ FOR RECON DENIED NO APPEAL FILED—
May 11, 2011RDX1ACTION FOR REQ FOR RECON DENIED NO APPEAL FILED E-MAILED—
May 11, 2011RRDXACTION REQ FOR RECON DENIED NO APPEAL FILED COUNTED NOT MAILED—
Apr 8, 2011TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Apr 8, 2011CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 8, 2011ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Apr 7, 2011GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Apr 7, 2011GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Apr 7, 2011CNFRSU - FINAL REFUSAL - WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Mar 2, 2011TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Mar 2, 2011CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 16, 2011ALIEASSIGNED TO LIE—
Feb 15, 2011TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 1, 2010GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 1, 2010GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 1, 2010CNRTSU - NON-FINAL ACTION - WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 4, 2010SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Nov 4, 2010UNTDREQUEST TO DIVIDE UNTIMELY, REFUSED, OR WITHDRAWN—
Oct 28, 2010EPPATEAS POST PUBLICATION AMENDMENT RECEIVED—
Oct 28, 2010AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Oct 8, 2010IUAFUSE AMENDMENT FILED—
Oct 8, 2010ERTDTEAS REQUEST TO DIVIDE RECEIVED—
Oct 8, 2010EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Apr 13, 2010NOAMNOA MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jan 19, 2010NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jan 19, 2010PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 14, 2009PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Dec 14, 2009ALIEASSIGNED TO LIE—
Nov 28, 2009CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 24, 2009DOCKASSIGNED TO EXAMINER—
Aug 24, 2009NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 24, 2009NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance